{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:01:05Z","timestamp":1777334465610,"version":"3.51.4"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and\/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment, and risk assessment may not be solved only from the antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next-generation sequencing (NGS) technology in diseases with a high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, we try to know the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects. This review will describe the related research of NGS technology in APS and provide more reference for the deep understanding of APS-related screening markers and disease pathogenesis.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1128245","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:20:31Z","timestamp":1684473631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome"],"prefix":"10.3389","volume":"14","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.02.019","article-title":"Clinical significance of anti-domain 1 \u03b22-glycoprotein I antibodies in antiphospholipid syndrome","volume":"153","author":"Iwaniec","year":"2017","journal-title":"Thromb Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04987-8","article-title":"Precision medicine and the antiphospholipid syndrome: what is the future","volume":"39","author":"Rodriguez-Pint\u00f3","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipidsyndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndromes","author":"Cervera","year":"2017","journal-title":"Thromb Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.3390\/ijms22084200","article-title":"Platelets and the antiphospholipid syndrome","volume":"22","author":"Huang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11910-021-01124-z","article-title":"Neurologic manifestations of the antiphospholipid syndrome - an update","volume":"21","author":"Leal Rato","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-020-00976-7","article-title":"Pediatric antiphospholipid syndrome: from pathogenesis to clinical management","volume":"23","author":"Rosina","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1900733","article-title":"Antiphospholipid syndrome: the need for new international classification criteria","volume":"17","author":"El Hasbani","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.autrev.2020.102689","article-title":"\"Non-criteria\" antiphospholipid syndrome: a nomenclature proposal","volume":"19","author":"Pires da Rosa","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: anti-\u03b22GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972012","article-title":"Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: diagnostic value added","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24520","article-title":"Development of a new international antiphospholipid syndrome classification criteria phase I\/II report: generation and reduction of candidate criteria","volume":"73","author":"Barbhaiya","year":"2021","journal-title":"Arthritis Care Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320951260","article-title":"16th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera","year":"2020","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1177\/09612033211055010","article-title":"Summary of the 12th Meeting of the European Forum on antiphospholipid antibodies ONLINE","volume":"30","author":"Djokovic","year":"2021","journal-title":"Lupus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes252","article-title":"Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays","volume":"52","author":"Vikerfors","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0501-RA","article-title":"Review of clinical next-generation sequencing","volume":"141","author":"Yohe","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2013.09.006","article-title":"The next-generation sequencing revolution and its impact on genomics","volume":"155","author":"Koboldt","year":"2013","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2011.43","article-title":"Evaluation of next-generation sequencing software in mapping and assembly","volume":"56","author":"Bao","year":"2011","journal-title":"J Hum Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"631.e7","DOI":"10.1016\/j.cmi.2020.06.012","article-title":"Diagnostic accuracy of VIDISCA-NGS in patients with suspected central nervous system infections","volume":"27","author":"van Zeggeren","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2021.09.005","article-title":"Next-generation sequencing (NGS) to determine microbiome of herniated intervertebral disc","volume":"22","author":"Astur","year":"2022","journal-title":"Spine J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01139-4","article-title":"Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American college of medical genetics and genomics (ACMG)","volume":"23","author":"Rehder","year":"2021","journal-title":"Genet Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11926-021-01008-8","article-title":"Antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION): 10-year update","volume":"23","author":"Erkan","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.3390\/ijms22052588","article-title":"Understanding the pathophysiology of thrombotic APS through animal models","volume":"22","author":"Gandhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1055\/a-1701-2809","article-title":"Pathophysiology of antiphospholipid syndrome","volume":"122","author":"Green","year":"2022","journal-title":"Thromb Haemost"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.3390\/ijms21249551","article-title":"Genetic factors in antiphospholipid syndrome: preliminary experience with whole exome sequencing","volume":"21","author":"Barinotti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.014","article-title":"Genetic risk factors in thrombotic primary antiphospholipid syndrome: a systematic review with bioinformatic analyses","volume":"17","author":"Islam","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/1744666X.2021.1901581","article-title":"Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets","volume":"17","author":"Cecchi","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.gene.6364443","article-title":"Innate immune response gene expression profiles characterize primary antiphospholipid syndrome","volume":"9","author":"Bernales","year":"2008","journal-title":"Genes Immun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204600","article-title":"Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus","volume":"74","author":"Perez-Sanchez","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00773","article-title":"Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome","volume":"10","author":"Lonati","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.jaut.2022.102979","article-title":"The complement system and human autoimmune diseases","volume":"17","author":"Coss","year":"2022","journal-title":"J Autoimmun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211004","article-title":"P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance","volume":"219","author":"He","year":"2022","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrrheum.2017.220","article-title":"Moving towards a molecular taxonomy of autoimmune rheumatic diseases","volume":"14","author":"Barturen","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.41697","article-title":"A proinflammatory cytokine network profile in Th1\/Type 1 effector b cells delineates a common group of patients in four systemic autoimmune diseases","volume":"73","author":"Simon","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"\u00dcnl\u00fc","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2017-0502","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome","volume":"56","author":"Shi","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279208","article-title":"Vimentin\/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome","volume":"116","author":"Ortona","year":"2010","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02971","article-title":"Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria","volume":"9","author":"Litvinova","year":"2018","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.04.065","article-title":"Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome","volume":"495","author":"Zhang","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.006","article-title":"Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and treatment efficacy in pregnancies","volume":"46","author":"Mekinian","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/art.27345","article-title":"IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor","volume":"62","author":"Fredi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.24701","article-title":"Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome","volume":"60","author":"Yin","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B50","doi-asserted-by":"publisher","first-page":"31375","DOI":"10.1038\/srep31375","article-title":"'Atherothrombosis-associated microRNAs in antiphospholipid syndrome and systemic lupus erythematosus patients'","volume":"6","author":"P\u00e9rez-S\u00e1nchez","year":"2016","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315346","article-title":"Characterization of antiphospholipid syndrome atherothrombotic risk by unsupervised integrated transcriptomic analyses","volume":"41","author":"P\u00e9rez-S\u00e1nchez","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.11.011","article-title":"Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils","volume":"196","author":"Weeding","year":"2018","journal-title":"Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1209","article-title":"Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry","volume":"122","author":"Avcin","year":"2008","journal-title":"Pediatrics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5152\/eurjrheum.2019.19160","article-title":"Pediatric antiphospholipid syndrome","volume":"7","author":"Madison","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001358","article-title":"Diffuse alveolar hemorrhage in primary versus secondary antiphospholipid syndrome","volume":"27","author":"Sangli","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04642.x","article-title":"Human leukocyte antigen-DRB1 and -DQB1 genotyping in lupus patients with and without antiphospholipid syndrome","volume":"1173","author":"Kapitany","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.027","article-title":"Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: are they different entities","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320954520","article-title":"16th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome","volume":"29","author":"de Jes\u00fas","year":"2020","journal-title":"Lupus"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2017.46","article-title":"The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome","volume":"62","author":"Sugiura-Ogasawara","year":"2017","journal-title":"J Hum Genet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2018.03.005","article-title":"The relation between protein z polymorphism and the risk of thrombosis in Egyptian patients with antiphospholipid syndrome","volume":"11","author":"Eissa","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.07.006","article-title":"The H1 haplotype of the endothelial protein c receptor protects against arterial thrombosis in patients with antiphospholipid syndrome","volume":"169","author":"Plas\u00edn-Rodr\u00edguez","year":"2018","journal-title":"Thromb Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/biomedicines11010055","article-title":"Methylenetetrahydrofolate reductase 677T allele is a risk factor for arterial thrombosis in Chinese han patients with antiphospholipid syndrome","volume":"11","author":"Tang","year":"2022","journal-title":"Biomedicines"},{"key":"B71","doi-asserted-by":"publisher","first-page":"102675","DOI":"10.1016\/j.jaut.2021.102675","article-title":"Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: implications for thrombosis risk","volume":"122","author":"Krilis","year":"2021","journal-title":"J Autoimmun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.184416","article-title":"Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome","volume":"103","author":"P\u00e9rez-S\u00e1nchez","year":"2018","journal-title":"Haematologica"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702425","article-title":"Urine proteomics differentiate primary thrombotic antiphospholipid syndrome from obstetric antiphospholipid syndrome","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoy004","article-title":"ESHRE guideline: recurrent pregnancy loss","volume":"2","author":"Bender Atik","year":"2018","journal-title":"Hum Reprod Open"},{"key":"B75","article-title":"Development and validation of an antiphospholipid damage index: a multicenter, binational project","volume":"7","author":"Amigo","year":"1998","journal-title":"Lupus"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort","volume":"49","author":"Radin","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221078223","article-title":"Clinical and therapeutic value of the adjusted global antiphospholipid syndrome score in primary obstetric antiphospholipid syndrome","volume":"31","author":"Udry","year":"2022","journal-title":"Lupus"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315576858","article-title":"Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)","volume":"24","author":"Amigo","year":"2015","journal-title":"Lupus"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145177","article-title":"Risk scale for the diagnosis of antiphospholipid syndrome","volume":"70","author":"Sciascia","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.thromres.2020.11.027","article-title":"Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation","volume":"198","author":"Janjetovic","year":"2021","journal-title":"Thromb Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215820","article-title":"NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus","volume":"79","author":"Linge","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1128245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:20:36Z","timestamp":1684473636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1128245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2023.1128245"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1128245","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1128245"}}